Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Turns The Screws On Genzyme

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis goes public with a $69-per-share offer for Genzyme, while the biotech rebuffs the offer as "opportunistic."

You may also be interested in...



Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit

Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.

Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit

Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.

Sanofi And Genzyme: Do Big Pharmas And Orphan Drugs Fit Together?

Big pharmas from Pfizer to GlaxoSmithKline are expanding their initiatives in niche disease areas, but if Sanofi-Aventis acquires Genzyme as it hopes, the French drug maker could soon emerge as an orphan drug leader

Related Content

Topics

UsernamePublicRestriction

Register

PS071115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel